Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors-Reference-Cited by-同舟云学术

Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors

Published:2021-08-30 Issue:5 Volume:11 Page:1763-1776
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Chimalakonda Anjaneya,Burke James,Cheng Lihong,Catlett Ian,Tagen Michael,Zhao Qihong,Patel Aditya,Shen Jun,Girgis Ihab G.,Banerjee Subhashis,Throup John

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

https://link.springer.com/content/pdf/10.1007/s13555-021-00596-8.pdf

Reference27 articles.

1. Nogueira M, Puig L, Torres T. JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors. Drugs. 2020;80(4):341–51.

2. Kvist-Hansen A, Hansen PR, Skov L. Systemic treatment of psoriasis with JAK inhibitors: a review. Dermatol Ther (Heidelb). 2020;10(1):29–42.

3. Balogh EA, Bashyam AM, Ghamrawi RI, Feldman SR. Emerging systemic drugs in the treatment of plaque psoriasis. Expert Opin Emerg Drugs. 2020;25(2):89–100.

4. Howell MD, Kuo FI, Smith PA. Targeting the Janus kinase family in autoimmune skin diseases. Front Immunol. 2019;10:2342.

5. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175–87.

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JAK inhibitor selectivity: new opportunities, better drugs?;Nature Reviews Rheumatology;2024-09-09

2. New and emerging oral therapies for psoriasis;Drugs in Context;2024-08-01

3. Deucravacitinib: moderate-to-severe plaque psoriasis preventable?;Journal of Basic and Clinical Physiology and Pharmacology;2024-07-09

4. Complex patterns of multimorbidity associated with severe COVID-19 and long COVID;Communications Medicine;2024-07-08

5. Oral Psoriasis Therapies;Dermatologic Clinics;2024-07